



Title	KRAS, MYC, and ARF6 : inseparable relationships cooperatively promote cancer malignancy and immune evasion
Author(s)	Sabe, Hisataka
Citation	Cell Communication and Signaling, 21(1), 106 https://doi.org/10.1186/s12964-023-01130-3
Issue Date	2023-05-08
Doc URL	https://hdl.handle.net/2115/90514
Rights(URL)	https://creativecommons.org/licenses/by/4.0/
Type	journal article
File Information	Cell Commun Signal 21 106.pdf



REVIEW

Open Access



KRAS, MYC, and ARF6: inseparable relationships cooperatively promote cancer malignancy and immune evasion

Hisataka Sabe^{1*}

Abstract

Mutations in the *KRAS* gene and overexpression of protein products of the *MYC* and *ARF6* genes occur frequently in cancer. Here, the inseparable relationships and cooperation of the protein products of these three genes in cancer malignancy and immune evasion are discussed. mRNAs encoded by these genes share the common feature of a G-quadruplex structure, which directs them to be robustly expressed when cellular energy production is increased. These three proteins are also functionally inseparable from each other, as follows. 1) *KRAS* induces *MYC* gene expression, and may also promote eIF4A-dependent *MYC* and *ARF6* mRNA translation, 2) *MYC* induces the expression of genes involved in mitochondrial biogenesis and oxidative phosphorylation, and 3) *ARF6* protects mitochondria from oxidative injury. *ARF6* may moreover promote cancer invasion and metastasis, and also acidosis and immune checkpoint. Therefore, the inseparable relationships and cooperation of *KRAS*, *MYC*, and *ARF6* appear to result in the activation of mitochondria and the driving of *ARF6*-based malignancy and immune evasion. Such adverse associations are frequent in pancreatic cancer, and appear to be further enhanced by *TP53* mutations.

Keywords AMAP1, *ARF6*, Cancer immune evasion, Cancer malignancy, eIF4A, *KRAS*, *MYC*, Mitochondria, mTOR, G-quadruplex structure, *TP53*

Background

Mutations in the *KRAS* gene, and protein overexpression of *c-MYC* (referred to as *MYC*) and *ARF6* are frequent in many types of cancers. *KRAS* mutations are well known to promote oncogenesis [1], *MYC* overexpression is thought to promote tumor growth [2], and *ARF6* overexpression has been shown to promote invasion and metastasis [3]. Moreover, *TP53* is the most frequently mutated gene in human cancers [4]. Cancer cells with mutations and/or overexpression of these genes are intractable, and often exhibit recurrence. Pancreatic

ductal adenocarcinoma (PDAC) is a typical example, in which mutations in the *KRAS* and *TP53* genes, and the overexpression of *MYC* and *ARF6* proteins are all prevalent [5–7]. The 5-year patient survival rate of PDAC remains very low [8], and unfortunately immune checkpoint inhibitor therapy has not yet been approved for PDAC because it is not effective alone.

Here discussed are that *KRAS*, *MYC*, and *ARF6* are biochemically and functionally closely related with each other in promoting cancer malignancy and immune evasion. *TP53* mutations may enhance the relationships and cooperation of these three musketeers by upregulating glucose uptake and the mevalonate pathway (MVP) activity, and by stopping the p53-mediated induction of certain miRNAs.

*Correspondence:

Hisataka Sabe
sabeh@med.hokudai.ac.jp

¹ Department of Molecular Biology, Graduate School of Medicine, and Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Common features of *KRAS*, *MYC*, and *ARF6* mRNAs

KRAS, *MYC*, and *ARF6* mRNAs have the G-quadruplex (G4) structure in the 5'-untranslated region [9]. Although the G4 structures of various mRNAs demonstrate some differences, mRNAs with G4 generally require eIF4A, which is an RNA helicase that uses ATP to unwind the secondary structure of mRNA during translation [9]. Thus, an increase in cellular energy production appears to be a prerequisite for the robust expression of *KRAS*, *MYC*, and *ARF6* proteins. Moreover, the eIF4A-mediated mRNA translation process can be the rate-limiting step for protein expression. Indeed, *ARF6* mRNA levels do not necessarily correlate with *ARF6* protein levels in cancer cells [10]. Moreover, mutations in *TP53* are known to promote cellular glucose uptake [11]. Thus, *TP53* mutations appear to be efficient in increasing *KRAS*, *MYC*, and *ARF6* protein expression via promoting glycolysis and ATP production.

KRAS promotes *MYC* and *ARF6* protein expression

MYC gene expression is downstream of RAS signaling [12]. Hence, *MYC* will be constitutively expressed in the presence of oncogenic mutations of *KRAS*. Moreover, *KRAS* may also promote the eIF-4A-dependent translation of *MYC* and *ARF6* mRNAs [7, 13]. In this process, *KRAS* first induces the expression of genes encoding transcription factors, such as TEAD3 and ETV4, which suppress expression of the *PDCD4* gene, which is translated into the negative regulator of eIF-4A [7]. Thus, *KRAS* mutations appear to cause the overexpression of *MYC* and *ARF6* proteins in cancer cells. Moreover, growth factor receptor tyrosine kinases (RTKs) are frequently overexpressed in cancer. RAS is located downstream of RTK signaling. Thus, not only *RAS* mutations, but the overexpression of RTKs and their activation might also often cause *ARF6* and *MYC* overexpression.

Why is *KRAS* mutated instead of other *RAS* isoforms in cancer?

There is a marked bias among cancer types as to which genes among the *RAS* isoforms are frequently mutated [14]. *KRAS* mutations are predominant in cancer, particularly in PDAC, and 90% to 95% of PDACs have this mutation [1, 5]. *KRAS* mutations are also frequently found in colorectal cancer, in which approximately 35% have *KRAS* mutations [14]. On the other hand, *NRAS* mutations are found in 15% to 20% of melanomas, and *HRAS* mutations are found in about 10% of bladder cancers and cervical cancers [14]. Moreover, the mutational spectrum (*i.e.*, which amino acid is frequently

mutated) of *KRAS* and other *RAS* genes also varies substantially among tumors of different tissue origin, and among tumors of patients with different ages at diagnosis [15].

Unlike other *RAS* genes, the *KRAS* gene utilizes rare codons [16]. Thus, the amount of rare tRNAs present will be rate-limiting for *KRAS* protein expression. Very strong signals from RAS may induce cell death [17]. Thus, two features of *KRAS*, the G4 structure in the mRNA and the rare codons in the gene, will prevent the excessive expression of its protein product, and hence its mutations may be favored over mutations in other *RAS* genes in certain types of cancers. However, this notion still may not fully explain why *KRAS* mutations are so much more common in PDAC than in other types of cancer.

Each isoform of the RAS protein undergoes different lipid modifications through different intracellular transport pathways, and hence localize to different microdomains of the plasma membrane [18–20]. Furthermore, oncogenic RAS proteins and the wild-type RAS protein may play independent and nonredundant roles [21]. Detailed elucidation of the biological significance of these issues, including those described above, will lead to further understanding of the biology of cancer. In particular, the fact that almost all PDACs selectively use *KRAS* over other RAS-GTPases may be hiding some important secret in this cancer and could be a whole new key to drug development against PDAC.

ARF6 in cancer

The ARF-GTPases appear to be the evolutionarily oldest type of small-GTPases, and play essential roles in the life of cells [22, 23]. This family of small-GTPases regulate membrane remodeling and intracellular trafficking [24]. *ARF6* is the only member of the class III ARF-GTPases, and primarily regulates the recycling of plasma membrane components and certain cell surface receptors at the cell periphery [25]; and regulates cell adhesion and invasion [26], in which *ARF6* appears to play essential roles in cell–matrix interactions and cell–cell interactions, as well as interactions with microenvironments and stromal cells (see later). Overexpression of the *ARF6* protein is frequently seen in various types of cancers, including those of the pancreas, breast, kidney, lung, and head and neck, to be statistically correlated with poor patient survival [7, 27–31].

Like other small-GTPases, GTP-*ARF6* uses effector proteins for its downstream signaling. AMAP1 (also called ASAP and DDEF1) is a major downstream effector of *ARF6* [32]. Like *ARF6*, the AMAP1 protein can be overexpressed by *KRAS* mutations (7; see later). AMAP1 contains several protein–protein interaction modules, including an SH3 domain and proline-rich regions [32].

Via the interaction of AMAP1 with PRKD2 and EPB41L5, ARF6 signaling upregulates β 1-integrins and downregulates E-cadherin, respectively [33, 34]. The upregulation of integrins and the downregulation of E-cadherin are hallmarks of epithelial-mesenchymal transition (EMT). EPB41L5 is a mesenchymal-specific protein that is induced upon EMT [35]. The occurrence of EMT in cancer cells is fundamentally involved in the promotion of invasion and metastasis, as well as in other malignancies such as fibrosis, and is closely associated with cancer cell resistance to treatments, including chemotherapy and immunotherapy [36–39]. Therefore, the ARF6-AMAP1 pathway appears to be crucial in promoting cancer malignancy in association with EMT. Intriguingly, moreover, the ARF6-AMAP1 pathway is also linked to the processes of intracellular recycling and cell surface expression of PD-L1 and carbonic anhydrase 9 (CA9), and hence may promote the onset of immune checkpoint (*i.e.*, enhanced PD-L1 expression at the cell surface) and acidosis (*i.e.*, enhanced CA9 expression at the cell surface), which both favor cancer immune evasion [7, 40]. In particular, with respect to resistance to immunotherapy, increasing intracellular recycling activity of PD-L1 by ARF6 can allow new PD-L1 molecules to continuously appear on the cell surface which may bind to PD-1 molecules on immune cells before these PD-L1 molecules blocked by their Abs. The ARF6-AMAP1 pathway furthermore has the ability to promote cancer radioresistance, by promoting the intracellular distribution of mitochondria ([41], see later).

ARF6 converts growth stimulation into malignancy and immune evasion

The overexpression of RTKs is a major risk factor of cancer, as mentioned earlier. Such RTKs include epidermal growth factor receptor, HER2 (also called ERB-B2 or NEU), platelet-derived growth factor receptor (PDGFR), and vascular endothelial cell growth factor receptor. ARF6 can be activated by these RTKs, in which a guanine nucleotide exchanger (GEF) for ARF6, GEP100, directly binds to the tyrosine phosphorylation sites of RTKs [42]. Through this mechanism, ARF6 may convert growth stimulation into invasion, metastasis, and immune evasion [7, 42]. Furthermore, as RTK signaling can be linked to the overexpression of ARF6 and AMAP1 proteins via the activation of RAS (see later), the overexpression of RTKs may enhance ARF6 signaling in various ways.

RTKs are not a major risk factor of clear cell renal cell carcinoma. This type of cancer often overexpresses autotaxin, which is also known as ectonucleotide pyrophosphatase/phosphodiesterase 2, and produces lysophosphatidic acid (LPA) from lysophosphatidylcholine extracellularly. LPA activates ARF6 via G-protein-coupled receptors (GPCRs), in which $G\alpha_{12}$ activated

under the GPCRs employs EFA6, which is a GEF for ARF6 [30]. Through this mechanism, the overexpression of autotaxin acts as risk factors driving EMT-associated malignancy and the drug resistance of renal cancer [30].

Unique properties of AMAP1

AMAP1 has a domain homologous to GTPase-activating proteins (GAPs) of ARF-GTPases, and demonstrates GAP activity against the class I ARF-GTPases [43]. On the other hand, AMAP1 binds stably to GTP-ARF6, but not to GDP-ARF6, via the GAP domain, regardless of the presence of Mg^{2+} [44]. Intriguingly, ASAP3, a close isoform of AMAP1, has been shown to demonstrate GAP activity against GTP-ARF6 in the presence of Ca^{2+} [45]. Thus, it is likely that AMAP1 also requires Ca^{2+} to hydrolyze GTP-ARF6, and this should be tested in the future.

KRAS and TP53 mutations cooperatively activate the ARF6-AMAP1 pathway

The ARF6-AMAP1 pathway appears to be the major target of *KRAS/TP53* double mutations. Gain-of function mutations of *TP53* promote ARF6 activation by RTKs [46]. In this process, increased expression of the MVP enzymes by gain-of function mutations of *TP53* [47] promotes the geranyl-geranylation of RAB11b, and geranyl-geranylated RAB11b then recruits ARF6 to the plasma membrane [46]. The gain-of function mutant-p53 was moreover shown to induce PDGFR β in PDAC cells [48]; and PDGFR β , when activated by ligands, activates ARF6 via GEP100 [7]. In line with this, statins, which are inhibitors of MHG-CoA reductase of the MVP and hence inhibit the production of geranyl-geranyl pyrophosphate, block ARF6 activation and inhibit cancer malignancy [46]. Furthermore, wild-type p53 may induce the expression of miRNAs, such as miR-96 and miR-182 that target *AMAP1* mRNA, and hence mutations in *TP53* cause an increase in *AMAP1* mRNA levels [49].

KRAS may also promote *AMAP1* protein expression. *AMAP1* mRNA contains a 5'-terminal oligopyrimidine-like sequence, and requires eIF4E for translation [7]. *KRAS* signaling may activate mTORC1 [50], and mTORC1 then phosphorylates 4EBP1, releasing eIF4E from 4EBP1 [51]. Thus, *KRAS* mutations appear to promote *AMAP1* mRNA translation via enhancing mTORC1 and eIF4E [7]. As a result, collectively, ARF6 and AMAP1 proteins are both often overexpressed by *KRAS* mutations, and also by normal RAS activated by RTKs. Indeed, the pattern of AMAP1 overexpression among cancers is similar to that of ARF6 overexpression [10, 32].

KRAS, MYC, and ARF6 cooperatively activate mitochondria

MYC is a transcriptional cofactor binding directly to DNA. Chromatin immunoprecipitation studies have

suggested more than thousands of genes as direct targets of MYC binding [52, 53]. Intriguingly, several hundreds of these genes are involved in mitochondrial biosynthesis, and also mitochondrial functions, including oxidative phosphorylation (OXPHOS), which produces ATP aerobically [54, 55]. As KRAS induces MYC, mitochondria appear to be the primary target of KRAS and MYC in cancer [56].

ARF6 is also closely related to mitochondria. Because mitochondrial OXPHOS involves the production of reactive oxygen species (ROS), mitochondrial aggregation carries the risk of excessive ROS production by a ROS-induced ROS release (RIRR)-like mechanism [57]. Binding of the mitochondrial motor proteins RhoT1 and TRAK2 promotes retrograde mitochondrial transport [58, 59], which may lead to the accumulation of mitochondria near the nucleus. On the other hand, the ARF6-AMAP1 pathway, when activated, promotes the recycling of β 1-integrin and its localization to focal adhesions via PRKD2, which in turn promotes the recruitment of integrin-linked kinase (ILK) to focal adhesions, and ILK then inhibits the RhoT1-TRAK2 association [41]. Through this mechanism, ARF6 may facilitate the forward transport and spatial distribution of mitochondria within the cell, and avoid RIRR-based oxidative injury of mitochondria [41]. In line with this, blocking the ARF6-AMAP1 pathway increased the oxidative stress of cancer cells, in association with substantial mitigation of the radioresistance [41].

The ARF6-mitochondria link appears to be important for cancer cell invasion and metastasis. The ARF6-AMAP1 pathway promotes the invasion and metastasis of cancer cells, whereas cell invasion often involves cells entering physically narrow pathways, in which mitochondria tend to be densely accumulated. Cancer cells may moreover encounter an oxygen-rich environment during invasion and metastasis, which increases mitochondrial OXPHOS, which in turn increases the risk of RIRR. Intriguingly, moreover, the link between ARF6 and mitochondria only occurs in cell invasion, but not in two-dimensional cell migration [41]. Therefore, the link between ARF6 and mitochondria appears to protect mitochondria from oxidative injury, specifically during invasion and metastasis.

Collectively, as KRAS and MYC activate mitochondria, KRAS activates ARF6, and ARF6 protects mitochondria, it is likely that KRAS, MYC, and ARF6 cooperatively control mitochondria in their biogenesis, metabolism, and integrity, which are all essential for cancer growth and survival; and, again, these events are likely to be further strengthened when *TP53* is mutated (Fig. 1).

Conclusions

Here I discussed the mutually inseparable relationships and cooperation of KRAS, MYC, and ARF6 in cancer malignancy and immune evasion. The molecular bases of their interrelationships are the common usage of G4 in mRNAs, and the promotion of MYC and ARF6 expression by KRAS. Their relationships and cooperation may be strengthened




Fig. 1 Inseparable relationships and cooperation of KRAS, MYC, and ARF6 in cancer. Mutant *KRAS* induces *MYC* gene expression and promotes *MYC* and *ARF6* G4-mRNA translation via increasing eIF4A activity. *MYC* promotes mitochondrial biogenesis and OXPHOS, whereas *ARF6* protects mitochondria from oxidative injury by promoting anterograde trafficking of mitochondria which is linked to the activation of integrin recycling and cell invasion by *ARF6*. Mitochondria generate ATP by OXPHOS, which may promote eIF4A activity, which in turn promotes translation of *MYC* and *ARF6* mRNAs. *TP53* mutations enhance glucose uptake, resulting in increased anaerobic ATP production by glycolysis to facilitate the translation of G4 mRNAs even under hypoxia (*i.e.*, low mitochondrial OXPHOS). Enhanced glucose uptake may also fuel mitochondrial metabolism, including OXPHOS. *TP53* mutations enhance *ARF6* activation and signaling via activating MVP and stopping expression of miRNAs that target *AMAP1* mRNA (see Fig. 2)




Fig. 2 KRAS, TP53, and MYC cooperatively drive ARF6-mediated cancer malignancy and immune evasion, accompanied with increased mitochondrial activity. Activation of ARF6 by growth factors or LPA triggers a series of intracellular signaling pathways via its downstream effector, AMAP1, that promote cancer cell invasion and metastasis, immune evasion, acidosis, and oxidative/radio-resistance, respectively, and play critical roles in immune evasion and therapeutic resistance (see text for details). ARF6, KRAS, and MYC are inseparable from each other at the molecular level in promoting cancer malignancy and immune evasion. ARF6, KRAS and MYC mRNAs have the G4 structure and require high eIF4A activity for their translation. Thus, the mRNA G4 structure and eIF4A are promising targets to defeat these three evil musketeers in cancer drug development

when TP53 is mutated, in which the TP53 mutation promotes G4 translation by promoting energy production, assists ARF6 activation, and increases AMAP1 mRNA levels. The end result of this cooperation appears to be the promotion of ARF6-based cancer invasion, metastasis, acidosis, radioresistance, and immune evasion, accompanied with increased mitochondrial activity (Fig. 2).

Pharmacological inhibitors, such as the eIF4A inhibitor silvestrol, which blocks ARF6 and MYC mRNA translation, and the MVP inhibitor statins, which block ARF6 activation, can effectively mitigate ARF6-based malignancies and treatment resistance [7, 40, 41, 46]. Consequently, the combination of an anti-PD-1 antibody with silvestrol very effectively blocked PDAC growth in a KPC mouse model [13]. G4 structures are also found in many human infectious microorganisms, including the malaria parasite and SARS-COV-2 virus. Thus, the development of drugs that target the G4 structure and eIF4A is now very active worldwide. Moreover, certain types of KRAS mutations are now known to be druggable [60, 61].

Lastly, cancer patients often have circulatory disturbances [62–65], which may affect peripheral blood mononuclear cells and hence impair immunity [66]. Immunity is essential not only in immunotherapy but also in chemotherapy-based cancer treatments [67]. Thus, as we have discussed recently [68], improving circulatory problems might be a prerequisite for effective cancer therapeutics in many cases, including those targeting KRAS and G4.

Abbreviations

CA9	Carbonic anhydrase 9
EMT	Epithelial-mesenchymal transition
GAP	GTPase-activating protein
GEF	Guanine nucleotide exchange factor
ILK	Integrin-linked kinase
G4	G-quadruplex structure
LPA	Lysophosphatidic acid
PDAC	Pancreatic ductal adenocarcinoma
PDGFR	Platelet-derived growth factor receptor
ROS	Reactive oxygen species
RTK	Receptor tyrosine kinase

Acknowledgements

I thank all members of my laboratory for their sincere cooperation with me for long periods of time, Dr. Haruka Handa for his help in creating Fig. 2, and Dr. H. A. Popiel for critical reading of the manuscript.

Author's contributions

HS wrote the manuscript and prepared Figs. 1 and 2, with partial cooperation from Haruka Handa in preparing Fig. 2. The author(s) read and approved the final manuscript.

Funding

This work was supported by Grants-in-aid from the Ministry of Education, Science, Sports and Culture of Japan, and grants from the Takeda Science Foundation, the Mitsubishi Foundation, the Uehara Memorial Foundation, and the Suzuken Memorial Foundation to H. Sabe.

Availability of data and materials

Not applicable.

Declarations**Ethics approval and consent to participate**

Not applicable.

Consent for publication

Not applicable.

Competing interests

The author declare no competing interests.

Received: 4 February 2023 Accepted: 15 April 2023

Published online: 08 May 2023

References

- Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. *Cancer Res.* 2012;72:2457–67.
- Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. *Signal Transduct Target Ther.* 2018;3:5.
- Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. *J Biochem.* 2003;134:485–9.
- Olivier M, Hollstaein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* 2010;2:a001008.
- Raphael BJ, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell.* 2017;32:185–203.
- Mahlamaki EH, et al. Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. *Genes Chrom Cancer.* 2002;35:353–8.
- Hashimoto H, et al. ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer. *Proc Natl Acad Sci USA.* 2019;116:17450–9.
- Bengtsson A, Andersson R, Ansari D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data. *Sci Rep.* 2020;10:16425.
- Wolfe AL, et al. RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer. *Nature.* 2014;513:65–70.
- Hashimoto S, et al. Requirement for Arf6 in breast cancer invasive activities. *Proc Natl Acad Sci USA.* 2004;101:6647–52.
- Schwartzberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. *Cancer Res.* 2004;64:2627–33.
- Kerkhoff E, et al. Regulation of c-myc expression by Ras/Raf signalling. *Oncogene.* 1998;16:211–6.
- Hashimoto A, et al. Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer. *Cell Comm Signal.* 2021;18:54.
- <https://cancer.sanger.ac.uk/cosmic>
- Serebriiski IG, et al. Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. *Nat Commun.* 2019;10:3722.
- Lampson B, et al. Rare codons regulate KRas oncogenesis. *Curr Biol.* 2013;23:70–5.
- Downward J. Ras signalling and apoptosis. *Curr Opin Genet Dev.* 1998;8:49–54.
- Ahearn IM, Haigis K, Bar-Sagi D, Phillips MR. Regulating the regulator: post-translational modification of RAS. *Nat Rev Mol Cell Biol.* 2011;13:39.
- Ahearn IM, Zhou M, Phillips MR. Posttranslational modifications of RAS proteins. *Cold Spring Harb Perspect Med.* 2018;8:a031484.
- Campbell SL, Phillips MR. Post-translational modification of RAS proteins. *Curr Opin Struct Biol.* 2021;71:180.
- Young A, Lou D, McCormick F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. *Cancer Discov.* 2013;3:112–23.
- Li Y, et al. Functional genomic analysis of the ADP-ribosylation factor family of GTPases: phylogeny among diverse eukaryotes and function in *C. elegans*. *FASEB J.* 2004;18:1834–50.
- Vargova R, et al. A Eukaryote-wide perspective on the diversity and evolution of the ARF GTPase protein family. *Genome Biol Evol.* 2021;13:evab157.
- D'Souza-Schorey CP. ARF proteins: roles in membrane traffic and beyond. *Nat Rev Mol Cell Biol.* 2006;7:347–58.
- Donaldson JG. Multiple roles for Arf6: sorting, structuring, and signaling at the plasma membrane. *J Biol Chem.* 2003;278:41573–6.
- Sabe H. Requirement for Arf6 in cell adhesion, migration, and cancer cell invasion. *J Biochem.* 2003;134:485–9.
- Hashimoto S, et al. Requirement for Arf6 in breast cancer invasive activities. *Proc Natl Acad Sci USA.* 2004;101:6647–52.
- Menju T, et al. Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma. *PLoS ONE.* 2011;6:e25301.
- Sato H, et al. High level expression of AMAP1 protein correlates with poor prognosis and survival after surgery of head and neck squamous cell carcinoma patients. *Cell Comm Signal.* 2014;12:17.
- Hashimoto S, et al. Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer. *Nat Commun.* 2016;7:10656.
- <https://www.proteinatlas.org/ENSG00000165527-ARF6/pathology>
- Onodera Y, et al. Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. *EMBO J.* 2005;24:963–73.
- Onodera Y, et al. Rab5c promotes AMAP1-PRKD2 complex formation to enhance $\beta 1$ integrin recycling in EGF-induced cancer invasion. *J Cell Biol.* 2012;197:983–96.
- Hashimoto A, et al. ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis, and drug resistance. *Oncogenesis.* 2016;5:e259.
- Hirano M, et al. EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. *J Cell Biol.* 2008;182:1217–30.
- Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene.* 2010;29:4741.
- Terry S, et al. New insights into the role of EMT in tumor immune escape. *Mol Oncol.* 2017;11:824.
- De Las RJ, et al. Cancer drug resistance induced by EMT: novel therapeutic strategies. *Arch Toxicol.* 2021;95:2279.
- Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. *EMBO J.* 2021;40:e108647.
- Horikawa M, et al. Dual roles of AMAP1 in the transcriptional regulation and intracellular trafficking of carbonic anhydrase IX. *Transl Oncol.* 2022;15:101258.
- Onodera Y, et al. Arf6-driven cell invasion is intrinsically linked to TRAK1-mediated mitochondrial anterograde trafficking to avoid oxidative catastrophe. *Nat Commun.* 2018;9:2682.
- Morishige M, et al. GEP100 links epidermal growth factor receptor signaling to Arf6 activation to induce breast cancer invasion. *Nat Cell Biol.* 2008;10:85–92.
- Brown MT, et al. ASAP1, a phospholipid-dependent Arf GTPase-activating protein that associates with and is phosphorylated by Src. *Mol Cell Biol.* 1998;18:7038–51.

44. Sabe H, et al. ArfGAP family proteins in cell adhesion, migration and tumor invasion. *Curr Opin Cell Biol.* 2006;18:558–64.
45. Ismail SA, et al. The structure of an Arf-ArfGAP complex reveals a Ca²⁺ regulatory mechanism. *Cell.* 2010;141:812–21.
46. Hashimoto A, et al. P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. *J Cell Biol.* 2016;213:81–95.
47. Freed-Pastor WA, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. *Cell.* 2012;148:244–58.
48. Weissmueller S, et al. Mutant p53 drives pancreatic cancer metastasis through cell- autonomous PDGF receptor β signaling. *Cell.* 2014;157:382–94.
49. Handa H, et al. Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells. *Cell Commun Signal.* 2018;16:94.
50. Pylayeva-Gupta Y, Grabock E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. *Nat Rev Cancer.* 2011;11:761–74.
51. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol.* 2011;12:21–35.
52. Zeller Kl, et al. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome Biol.* 2003;4:R69.
53. Zeller Kl, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proc Natl Acad Sci USA.* 2006;103:17834–9.
54. Li F, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. *Mol Cell Biol.* 2005;25:6225–34.
55. Kim J, Lee J, Iyer VR. Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-Box usage in vivo. *PLoS ONE.* 2008;3:e1798.
56. Kimmelman AC. Metabolic dependencies in RAS-driven cancers. *Clin Cancer Res.* 2015;21:1828–34.
57. Zorov DB, et al. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J Exp Med.* 2000;192:1001–14.
58. van Spronsen M, et al. TRAK/Milton motor-adaptor proteins steer mitochondrial trafficking to axons and dendrites. *Neuron.* 2013;77:485–502.
59. Fu MM, Holzbaur ELF. Integrated regulation of motor-driven organelle transport by scaffolding proteins. *Trends Cell Biol.* 2014;24:564–74.
60. Uprety D, Adjei AA. KRAS: from undruggable to a druggable cancer target. *Cancer Treat Rev.* 2020;89:102070.
61. Huang L, et al. KRAS mutation: from undruggable to druggable in cancer. *Signal Transduct Target Ther.* 2021;6:386.
62. Hasin T, et al. Patients with heart failure have an increased risk of incident cancer. *J Am Coll Cardiol.* 2013;62:881–6.
63. Banke A, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow- up study. *Eur J Heart Fail.* 2016;18:260–6.
64. Hasin T, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. *J Am Coll Cardiol.* 2016;68:265–71.
65. Sakamoto M, et al. Does the pathophysiology of heart failure prime the incidence of cancer? *Hypertens Res.* 2017;40:831–6.
66. Shirakawa R, et al. Mitochondrial reactive oxygen species generation in blood cells is associated with disease severity and exercise intolerance in heart failure patients. *Sci Rep.* 2019;9:14709.
67. Iida N, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. *Science.* 2013;342:969–70.
68. Takada S, et al. Cross-disease communication between cancer and heart failure provides a rational approach to prevention and treatment of both diseases. *Front Oncol.* 2022;12:1006322.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

